Factory Price (4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1 3-oxazolidin-2-one - 4-(4-Aminophenyl)morpholin-3-One CAS 438056-69-0 Rivaroxaban Intermediate – Ruifu

Manufacturer with High Purity and Competitive Price
Commercial Supply Rivaroxaban (CAS: 366789-02-8) Related Intermediates:
(S)-(+)-Glycidyl Phthalimide CAS: 161596-47-0
4-(4-Aminophenyl)morpholin-3-one CAS: 438056-69-0
2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]-1H-isoindole-1,3(2H)-dione 446292-07-5
5-Chlorothiophene-2-carboxylic acid CAS: 24065-33-6
Rivaroxaban CAS: 366789-02-8

4-(4-Aminophenyl)morpholin-3-one CAS: 438056-69-0 Synthesis Route

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer’s requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4-(4-Aminophenyl)morpholin-3-one (CAS: 438056-69-0) with high quality, it is an intermediate typically in the synthesis of Rivaroxaban (CAS: 366789-02-8). 

Rivaroxaban (Xarelto; CAS: 366789-02-8) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. Rivaroxaban also inhibits prothrombinase activity with IC50 of 2.1 nM. Rivaroxaban also shows a similar affinity to purified human and rabbit FXa (IC50 0.7 nM and 0.8 nM, respectively), but a lesser potency against purified rat FXa (IC50 3.4 nM). Endogenous human and rabbit FXa in plasma is inhibited to a similar extent by Rivaroxaban (IC50 21 nM and 21 nM, respectively), while 14-fold higher concentrations are required in rat plasma (IC50 290 nM). Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated drug transport up to concentrations of 100 μM in vitro.